No direct data yet available testing the new variant’s resistance to immunity from monoclonal antibodies and vaccines
Colchicine No Benefit Over Supportive Care for COVID-19
No significant reduction reported in mortality, ventilatory support, ICU admission, length of stay, serious adverse events; increase seen in adverse events, diarrhea
FDA Panel Mulls Merck COVID-19 Antiviral Pill
Expert panel will vote later Tuesday on whether to recommend authorizing the drug for high-risk patients
Omicron Variant Spurs New York Officials to Recommend Masking Indoors
So far, there are no confirmed cases of the omicron variant in New York City, according to the health commissioner
Thanksgiving Weekend Brought New COVID-19 Concerns: the Omicron Variant
On Saturday, the CDC issued a statement stressing that ‘no cases of this variant have been identified in the U.S. to date’
Decline in Infectious Conjunctivitis During COVID-19 Pandemic
Decrease in emergency department encounters for nonallergic conjunctivitis after adoption of public health measures to curb COVID-19
SARS-CoV-2 Infection Up >90 Days Since Second BNT162b2 Dose
Individuals who tested positive for SARS-CoV-2 had significantly longer time elapsed since vaccine injection
Merck’s COVID-19 Pill Appears Effective, but May Pose Pregnancy Risks: FDA
Given safety concerns, FDA scientists said Merck has agreed the drug will not be used in children.
Biden Pushes Vaccines, Masks as Best Defense Against Omicron Variant
News reports out of South Africa noted that COVID-19 cases from omicron have resulted in mostly mild symptoms
Variant Specific COVID-19 Vaccines Coming Soon
With the number of confirmed reports of the SARS-CoV-2 coronavirus variant known as Omicron increasing, many people are seeking protection from COVID-19 vaccines.
As of November 27, 2021, media reports indicate 95 Omicron virus infections, and about 1,004 probable cases have been reported in eight countries.
However, there is good news as variant targeted mRNA vaccines could become available in early 2022.